Search Results

Hoth Therapeutics, Inc. is scheduled to attend the EF Hutton Annual Global Conference in New York, NY.

ChemDiv, Inc, announced that Bill Farley, CEO, will participate in the EF Hutton Annual Global Conference.

Sonnet BioTherapeutics Holdings, Inc., a biopharmaceutical company developing innovative targeted biologic drugs, will be participating in the EF Hutton Annual Global Conference, which will take place on May 15, 2024 at The Plaza Hotel in New York.

Processa Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, announced that management will be participating in the EF Hutton Annual Global Conference being held May 15, 2024 at The Plaza Hotel in New York City.

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals”, the “Company”), a clinical-stage biopharmaceutical company, today announced that it will participate in the EF Hutton Annual Global Conference, which will take place on May 15, 2024, at The Plaza Hotel in New York City.

NanoViricides, Inc., a global leader in broad-spectrum antiviral nanomedicines, announces that Anil R. Diwan, Ph.D., the Company’s President and Executive Chairman, will be attending the EF Hutton Annual Global Conference, which will be held at The Plaza Hotel in New York, NY on Wednesday, May 15, 2024.

PAVmed Inc announced that Veris and The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, a National Cancer Institute-Designated Comprehensive Cancer Center, launched a pilot program and enrolled the first patients on the Veris Cancer Care Platform™ pursuant to a recently-executed memorandum of understanding.

The Foundation for the National Institutes of Health announces two additions to the FNIH Board of Directors: James W. Down, former Vice Chairman of Mercer Management Consulting, and Perry Steiner, Chairman and CEO of Xactus.

PAVmed Inc. announced that Veris and The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, a National Cancer Institute-Designated Comprehensive Cancer Center, have executed a memorandum of understanding to implement a pilot program where cancer patients would be enrolled on the Veris Cancer Care Platform™.

ADMA Biologics, Inc. announced Adam Grossman, President and Chief Executive Officer, will participate in a fireside chat at the Raymond James Institutional Investor Conference on March 6, 2024, at 11:35 a.m. ET.